Cenix BioScience Signs Framework Research Agreement with AstraZeneca for RNAi-Based Drug Discovery
News Mar 20, 2008
Cenix BioScience GmbH (Dresden) has announced that it has signed a framework research agreement with AstraZeneca Pharmaceuticals LP to advance the latter’s efforts in the discovery and validation of novel therapeutic drug targets.
Cenix will apply its well-established expertise in combining high throughput (HT) applications of RNAi-based gene silencing, the technology behind the 2006 Nobel Prize for Medicine, with high content phenotypic analyses in cultured human cells.
The initial project will involve a HT-RNAi screen using an assay strategy co-designed with AstraZeneca scientists to discover and validate novel oncology targets. Cenix will adapt and implement multi-parametric microscopy-based assays using the Cellenger image analysis platform from Munich-based Definiens, to generate detailed insights into the cellular functions and loss-of-function phenotypes of analyzed genes. Such RNAi datasets, now widely favored throughout the industry, offer a highly predictive and cost-effective basis for discovering and prioritizing targets for therapeutic drug development in a wide range of disease fields.
“We are very excited to begin working with AstraZeneca scientists to help advance their discovery pipeline with this powerful and well-proven technology,” said Dr. Christophe Echeverri, CEO/CSO of Cenix.
“We look forward to driving this relationship beyond the initial pilot through to multiple projects, as we have successfully done with other major pharma partners: by exceeding expectations on scientific and strategic excellence, and delivering the most detailed and professional reporting available in this field,” Dr. Echeverri added.
Genome-wide association studies (GWAS) look at large populations to find genes that contribute to common, multi-gene traits like height or obesity. These comprehensive studies frequently turn up large numbers of tiny genetic variations that occur more often in people who are tall, obese, etc. So which genes should scientists investigate further?READ MORE
In recent years, numerous studies have shown that people who don't get enough sleep are at greater risk of stroke and heart attack. A study found that people who sleep fewer than 7 hours per night have lower blood levels of three physiological regulators, or microRNAs, which influence gene expression and play a key role in maintaining vascular health.